» Articles » PMID: 10504012

The Calgary Depression Rating Scale for Schizophrenia: Development and Interrater Reliability of a German Version (CDSS-G)

Overview
Journal J Psychiatr Res
Specialty Psychiatry
Date 1999 Sep 30
PMID 10504012
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

A German version of the Calgary Depression Rating Scale for Schizophrenia (CDSS-G) approved by the author of the original scale is presented comprising a semi-structured interview for 9 items to sensitively and specifically assess depression in schizophrenia and related disorders. The process of translation is outlined and the finally derived CDSS-G was investigated with respect to interrater reliability in three studies. To keep comparability with the CDSS source version a standard procedure was used. Two trained raters jointly assessed ten schizophrenic patients (study I). In a second study, videotapes with the CDSS-G were presented to clinically inexperienced raters (study II, N = 14/15) to test the agreement on the CDSS-G in this sample. Finally, in a third study clinically experienced researchers participated in a rater training (study III, N = 34). They carried out CDSS ratings on three patients with mild depressive symptoms. The dependence of interrater reliability on depression severity was investigated for all studied patients. Both intraclass correlation coefficients (ICC) and weighted kappa coefficients (kappa(w)) were calculated. The results revealed a high ICC = 0.97 in study I for the total CDSS-G score. Single item ICC values were all above 0.70. The results of study II revealed somewhat lower agreement on CDSS-G items and total scores in psychiatric novices with however acceptable values of kappa(w)>0.50 for the total scores. Study III yielded satisfactory results (0.66<kappa(w)<0.76) for clinically experienced psychiatrists in schizophrenic patients with mild depression. The results demonstrate adequate to excellent interrater reliability of the CDSS-G corroborating the results of the original version in different settings.

Citing Articles

Level of structural integration in people with schizophrenia and schizoaffective disorders - applicability and associations with clinical parameters.

Bayer S, Brocker A, Stuke F, Just S, Bertram G, Grimm I Front Psychiatry. 2024; 15:1388478.

PMID: 38911709 PMC: 11192590. DOI: 10.3389/fpsyt.2024.1388478.


Empathy in schizophrenia: neural alterations during emotion recognition and affective sharing.

Knobloch S, Leiding D, Wagels L, Regenbogen C, Kellermann T, Mathiak K Front Psychiatry. 2024; 15:1288028.

PMID: 38855645 PMC: 11157094. DOI: 10.3389/fpsyt.2024.1288028.


Cannabidiol versus placebo as adjunctive treatment in early psychosis: study protocol for randomized controlled trial.

Dixon T, Cadenhead K Trials. 2023; 24(1):775.

PMID: 38037108 PMC: 10691114. DOI: 10.1186/s13063-023-07789-w.


The multimodal Munich Clinical Deep Phenotyping study to bridge the translational gap in severe mental illness treatment research.

Krcmar L, Jager I, Boudriot E, Hanken K, Gabriel V, Melcher J Front Psychiatry. 2023; 14:1179811.

PMID: 37215661 PMC: 10196006. DOI: 10.3389/fpsyt.2023.1179811.


"Goals in Focus"-a targeted CBT approach for motivational negative symptoms of psychosis: study protocol for a randomized-controlled feasibility trial.

Schormann A, Pillny M, Hass K, Lincoln T Pilot Feasibility Stud. 2023; 9(1):72.

PMID: 37131247 PMC: 10152726. DOI: 10.1186/s40814-023-01284-4.